Brian Skorney
Stock Analyst at Baird
(3.99)
# 663
Out of 4,479 analysts
66
Total ratings
46.88%
Success rate
12.19%
Average return
Main Sectors:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $170 → $200 | $154.20 | +29.70% | 3 | Jun 21, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 | $68.40 | +16.96% | 1 | Jun 20, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $34 → $39 | $33.68 | +15.80% | 2 | Jun 17, 2024 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $28 | $14.02 | +99.71% | 1 | Jun 13, 2024 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $52 → $62 | $45.54 | +36.14% | 4 | May 23, 2024 | |
| SLNO Soleno Therapeutics | Initiates: Outperform | $72 | $39.73 | +81.22% | 1 | May 10, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Neutral | $20 → $2 | $1.19 | +68.07% | 4 | Apr 16, 2024 | |
| RGNX REGENXBIO | Maintains: Outperform | $34 → $39 | $10.75 | +262.79% | 3 | Mar 6, 2024 | |
| ANRO Alto Neuroscience | Initiates: Outperform | $32 | $11.10 | +188.29% | 1 | Feb 27, 2024 | |
| BIIB Biogen | Maintains: Outperform | $333 → $316 | $228.82 | +38.10% | 6 | Feb 14, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Initiates: Outperform | $58 | $34.17 | +69.74% | 1 | Dec 8, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $63 | $36.56 | +72.32% | 1 | Dec 8, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $140 → $148 | $137.49 | +7.64% | 3 | Aug 2, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $760 | $1,044.66 | -27.25% | 8 | Jun 28, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $280 → $325 | $473.78 | -31.40% | 14 | May 2, 2023 | |
| APLT Applied Therapeutics | Maintains: Outperform | $18 → $14 | $4.35 | +221.84% | 2 | Apr 25, 2023 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $130 → $90 | $13.45 | +569.14% | 3 | May 19, 2022 | |
| RPHM Reneo Pharmaceuticals | Initiates: Outperform | $28 | $1.51 | +1,754.30% | 1 | Jan 27, 2022 | |
| IMVT Immunovant | Downgrades: Neutral | n/a | $26.52 | - | 1 | Aug 3, 2021 | |
| VTGN VistaGen Therapeutics | Initiates: Outperform | n/a | $3.33 | - | 1 | May 20, 2021 | |
| VYGR Voyager Therapeutics | Downgrades: Neutral | n/a | $7.59 | - | 1 | Feb 26, 2021 | |
| AMGN Amgen | Downgrades: Underperform | n/a | $310.77 | - | 2 | Jan 31, 2020 | |
| CRIS Curis | Maintains: Outperform | n/a | $6.25 | - | 1 | May 7, 2018 | |
| BGNE BeiGene | Downgrades: Neutral | n/a | $143.93 | - | 1 | Nov 14, 2017 |
Sarepta Therapeutics
Jun 21, 2024
Maintains: Outperform
Price Target: $170 → $200
Current: $154.20
Upside: +29.70%
Gilead Sciences
Jun 20, 2024
Maintains: Neutral
Price Target: $80
Current: $68.40
Upside: +16.96%
Mirum Pharmaceuticals
Jun 17, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $33.68
Upside: +15.80%
Lexeo Therapeutics
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $14.02
Upside: +99.71%
Crinetics Pharmaceuticals
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $45.54
Upside: +36.14%
Soleno Therapeutics
May 10, 2024
Initiates: Outperform
Price Target: $72
Current: $39.73
Upside: +81.22%
Marinus Pharmaceuticals
Apr 16, 2024
Downgrades: Neutral
Price Target: $20 → $2
Current: $1.19
Upside: +68.07%
REGENXBIO
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $10.75
Upside: +262.79%
Alto Neuroscience
Feb 27, 2024
Initiates: Outperform
Price Target: $32
Current: $11.10
Upside: +188.29%
Biogen
Feb 14, 2024
Maintains: Outperform
Price Target: $333 → $316
Current: $228.82
Upside: +38.10%
Biohaven Pharmaceutical Holding Company
Dec 8, 2023
Initiates: Outperform
Price Target: $58
Current: $34.17
Upside: +69.74%
Xenon Pharmaceuticals
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $36.56
Upside: +72.32%
Neurocrine Biosciences
Aug 2, 2023
Maintains: Outperform
Price Target: $140 → $148
Current: $137.49
Upside: +7.64%
Regeneron Pharmaceuticals
Jun 28, 2023
Maintains: Neutral
Price Target: $800 → $760
Current: $1,044.66
Upside: -27.25%
Vertex Pharmaceuticals
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $473.78
Upside: -31.40%
Applied Therapeutics
Apr 25, 2023
Maintains: Outperform
Price Target: $18 → $14
Current: $4.35
Upside: +221.84%
Enanta Pharmaceuticals
May 19, 2022
Maintains: Outperform
Price Target: $130 → $90
Current: $13.45
Upside: +569.14%
Reneo Pharmaceuticals
Jan 27, 2022
Initiates: Outperform
Price Target: $28
Current: $1.51
Upside: +1,754.30%
Immunovant
Aug 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $26.52
Upside: -
VistaGen Therapeutics
May 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.33
Upside: -
Voyager Therapeutics
Feb 26, 2021
Downgrades: Neutral
Price Target: n/a
Current: $7.59
Upside: -
Amgen
Jan 31, 2020
Downgrades: Underperform
Price Target: n/a
Current: $310.77
Upside: -
Curis
May 7, 2018
Maintains: Outperform
Price Target: n/a
Current: $6.25
Upside: -
BeiGene
Nov 14, 2017
Downgrades: Neutral
Price Target: n/a
Current: $143.93
Upside: -